VERU

VERU INC. - 10-Q Filing Summary

Business Context and Reporting Period

Company: VERU INC. (VERU)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: Veru is a late clinical-stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases. Its primary drug candidates are enobosarm (for obesity and muscle preservation) and sabizabulin (for atherosclerotic cardiovascular disease). The company sold its commercial FC2 Female Condom business in December 2024, classifying it as discontinued operations.

Key Financial Metrics

Note: Non-operating income for the six months ended March 31, 2026, was primarily driven by a $3.81 million gain from the change in fair value of equity securities (ONCO Series D Preferred Stock and Warrants).

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by approximately 37% year-over-year for the six-month period (from $20.04 million to $12.64 million). This was driven by the wind-down of the Phase 2b QUALITY clinical study and reduced share-based compensation.
• Financing Activity: In October 2025, the company completed an underwritten public offering raising approximately $23.4 million in net proceeds. This significantly improved liquidity compared to the prior period.
• Discontinued Operations: The company recognized a $0.35 million gain in the current quarter related to the settlement of a dispute regarding the FC2 business sale. In the prior year, the company recorded a significant loss on the sale of the FC2 business.
• Equity Investments: The company converted and sold portions of its ONCO Series D Preferred Stock, realizing gains and reducing its exposure to the underlying equity.

Guidance, Outlook, and Risks

Going Concern Warning: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for twelve months following the issuance date of the financial statements. Current cash is insufficient to fund operations for that period without additional financing.

Clinical Outlook:

• Enobosarm: The company has initiated the Phase 2b PLATEAU clinical trial (first patient enrolled March 2026) to evaluate enobosarm in older patients with obesity receiving GLP-1 RA. The FDA has provided feedback that incremental weight loss is an acceptable primary endpoint.
• Sabizabulin: The company plans a small Phase 2 dose-finding study to assess inflammation reduction in patients with stable coronary artery disease.

Risks and Contingencies:

• Capital Needs: The company must raise additional capital through equity or debt offerings. Access to capital is constrained by the SEC "baby shelf" rule due to a public float under $75 million.
• Legal Proceedings: Multiple shareholder derivative lawsuits and a class action lawsuit (Ewing v. Veru Inc.) remain pending, alleging violations related to sabizabulin statements. A lawsuit from the FC2 purchaser (Clear Future) was partially settled regarding tax liabilities, but other claims remain.
• Regulatory: Success depends on FDA approval of clinical trial designs and eventual product candidates.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the company's immediate plan to secure financing given the "substantial doubt" disclosure.
• PLATEAU Trial Progress: Monitor enrollment rates and interim analysis timelines for the Phase 2b PLATEAU study, which is critical for the enobosarm program.
• Legal Exposure: Review the status of the Ewing class action and shareholder derivative suits to assess potential financial impact.
• Equity Dilution: Assess the impact of the recent public offering and outstanding warrants (7 million pre-funded warrants and 16.8 million Series A/B warrants) on future dilution.
• ONCO Settlement: Confirm the remaining value and liquidity of the ONCO Warrant held by Veru following the settlement of the ENTADFI asset sale.